| PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy JI Hsu, T Dayaram, A Tovy, E De Braekeleer, M Jeong, F Wang, J Zhang, ... Cell stem cell 23 (5), 700-713. e6, 2018 | 317 | 2018 |
| Highly efficient genome editing of murine and human hematopoietic progenitor cells by CRISPR/Cas9 MC Gundry, L Brunetti, A Lin, AE Mayle, A Kitano, D Wagner, JI Hsu, ... Cell reports 17 (5), 1453-1461, 2016 | 277 | 2016 |
| Evolution of protein phosphorylation across 18 fungal species RA Studer, RA Rodriguez-Mias, KM Haas, JI Hsu, C Viéitez, C Solé, ... Science 354 (6309), 229-232, 2016 | 91 | 2016 |
| Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms AS Sperling, VA Guerra, JA Kennedy, Y Yan, JI Hsu, F Wang, AT Nguyen, ... Blood, The Journal of the American Society of Hematology 140 (16), 1753-1763, 2022 | 71 | 2022 |
| Ocular complications of atopic dermatitis JI Hsu, SC Pflugfelder, SJ Kim Cutis 104 (3), 189-193, 2019 | 41 | 2019 |
| Antibiotic resistance in dermatology: The scope of the problem and strategies to address it RA Shah, JI Hsu, RR Patel, UN Mui, SK Tyring Journal of the American Academy of Dermatology 86 (6), 1337-1345, 2022 | 19 | 2022 |
| PPM1D in Solid and Hematologic Malignancies: Friend and Foe? L Zhang, JI Hsu, MA Goodell Molecular Cancer Research 20 (9), 1365-1378, 2022 | 7 | 2022 |
| Comprehensive analysis of genotype and prior exposures in therapy-related myeloid neoplasms (t-MNs) VA Guerra, Y Yuanqing, J Hsu, F Wang, M Alfayez, K Morita, X Song, ... Blood 134, 458, 2019 | 6 | 2019 |
| Expanded phenotypic and hematologic abnormalities beyond bone marrow failure in MECOM‐associated syndromes MM Lozano Chinga, AA Bertuch, Z Afify, K Dollerschell, JI Hsu, TD John, ... American Journal of Medical Genetics Part A 191 (7), 1826-1835, 2023 | 5 | 2023 |
| Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation L Maneix, P Iakova, SE Moree, JI Hsu, RM Mistry, F Stossi, P Lulla, Z Sun, ... Cancer research communications 2 (12), 1693-1710, 2022 | 2 | 2022 |
| The nucleotide kinase Nadk is required for ROS detoxification and constitutes a metabolic vulnerability of NOTCH1-Driven T-ALL E De Braekeleer, J Hsu, C Hervieu, K Tzelepis, S Indraccolo, AJ Warren, ... Blood 132, 2615, 2018 | 2 | 2018 |
| Nearly a Third of Clonal Hematopoiesis-Associated DNMT3A Mutations Reduce Protein Stability and May be Associated with Poorer Prognosis YH Huang, A Tovy, V Sundaramurthy, J Su, J Hsu, L He, A Guzman, ... Blood 132, 1315, 2018 | 2 | 2018 |
| A practical recipe to survey phosphoproteomes WC Edelman, KM Haas, JI Hsu, RT Lawrence, J Villén Shotgun Proteomics: Methods and Protocols, 389-405, 2014 | 2 | 2014 |
| S857 THE NUCLEOTIDE KINASE NADK CONSTITUTES A METABOLIC VULNERABILITY OF NOTCH1‐DRIVEN T‐ALL E De Braekeleer, M Gu, C Hervieux, J Ino Hsu, D Aspris, E Abby, ... HemaSphere 3, 382-383, 2019 | 1 | 2019 |
| SOD1 is a synthetic lethal target in PPM1D-mutant leukemia cells L Zhang, JI Hsu, ED Braekeleer, CW Chen, TD Patel, AG Martell, ... bioRxiv, 2023 | | 2023 |
| P1330: CYTOREDUCTIVE CHEMOTHERAPY COULD ACCELERATE THE LOSS OF CLONAL DIVERSITY IN HEMATOPOIETIC STEM CELLS AND PROMOTES THE CONVERGENT EVOLUTION OF THERAPY-RELATED CLONAL … H Uryu, K Saeki, J Nangalia, M Chapman, LI Zhao, J Hsu, ... HemaSphere 7 (S3), e181698b, 2023 | | 2023 |
| 3222–CLONAL COMPETITION: CHEMOTHERAPEUTIC STRESS DRIVES DOMINANCE OF TP53-OVER TET2-MUTANT STEM CELL CLONES K Wohlan, L Brunetti, J Hsu, K Matatall, R Murdaugh, L Zhang, A Guzman, ... Experimental Hematology 124, S160, 2023 | | 2023 |
| 3232–TARGETING SOD1 INDUCES SYNTHETIC LETHAL KILLING OF PPM1D-MUTANT LEUKEMIA CELLS L Zhang, J Hsu, E Braekeleer, CW Chen, T Dayaram, R Murdaugh, ... Experimental Hematology 124, S165, 2023 | | 2023 |
| Genome-Wide CRISPR Screen Reveals Dependency of PPM1D-mutant Cells on DNA Repair L Zhang, JI Hsu, ED Braekeleer, H Uryu, E Callen-Moreu, A Nussenzweig, ... Blood 140 (Supplement 1), 1994-1995, 2022 | | 2022 |
| Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis H Uryu, K Saeki, J Nangalia, M Spencer Chapman, L Zhao, JI Hsu, ... Blood 140 (Supplement 1), 2232-2233, 2022 | | 2022 |
